若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

mFreSR™

用于人胚胎干细胞和诱导多能干细胞的无血清冻存液
只有 %1
¥1,998.00

产品号 #(选择产品)

产品号 #05854_C

用于人胚胎干细胞和诱导多能干细胞的无血清冻存液

产品优势

  • 易使用
  • 无血清,专为与TeSR™维持培养基配合使用而优化
  • 细胞复苏效率高
  • 预筛选成分,确保批次间一致性
You may notice that your reagent packaging looks slightly different from images displayed here or from previous orders. Due to pandemic-related plasticware shortages, we are temporarily using alternative bottles for this product. Rest assured that the products themselves and how you should use them have not changed.

总览

mFreSR™是一种无血清的冻存液,用于人胚胎和诱导多能干细胞(ESC和iPSC)的冻存。mFreSR™含有DMSO,成分完整且随时可用。与mTeSR™ 1或mTeSR™ Plus配合使用时,mFreSR™无需使用饲养层和血清。使用mFreSR™冻存的人胚胎干细胞和诱导多能干细胞的复苏效率高于使用血清的传统复苏方法。

细胞类型
多能干细胞
 
种属

 
应用
冻存
 
品牌
mFreSR,TeSR
 
研究领域
干细胞生物学
 
制剂类别
无血清
 

实验数据

mFreSR™ Improves thawing efficiencies 5- to 10-fold over other reported methods

Figure 1. mFreSR™ Improves Thawing Efficiencies 5- to 10-Fold over Other Reported Methods

H9 hESCs were cryopreserved in mFreSR™ at the indicated passage number. Thawing efficiencies were analyzed by counting the number of surviving clumps after thawing.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
mFreSR™
Catalog #
05855, 05854
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
mFreSR™
Catalog #
05855, 05854
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (14)

文献 (28)

Human embryonic stem cell lines isolation, cultivation, and characterization Lagarkova MA et al. In vitro cellular & developmental biology. Animal 2010 APR

Abstract

A large number of human embryonic stem cell (hESC) lines have been derived worldwide since the first hESC line establishment in 1998. Despite many common characteristics,most important of which is the pluripotency,hESC lines vary significantly in their transcriptional profiles,genetic,and epigenetic state. These differences may arise both from individual genetics of the cell lines and from variations in their handling such as isolation and cultivation. In order to minimize the latter differences,the standardized protocols of cultivation and inter-laboratory comprehensive studies should be performed. In this report,we summarized our experience of derivation and characterization of hESC lines as well as of adaptation of hESCs to novel cultivation protocols. We have successfully derived five hESC lines and characterized them by previously established criteria,including expression of specific markers and the capacity to differentiate both in vitro and in vivo. Four of these lines,namely hESM01-04,were initially derived using mouse fibroblasts as a feeder and currently are maintained under feeder-free,serum-free conditions using mTeSR1 and Matrigel. The fifth line,hESMK05 was derived in feeder-free,serum-free conditions using mTeSR1 and Matrigel. Cell lines retain their pluripotent status and normal karyotype for more than 70 passages and are available to the scientific community.
Establishment of hESC lines from the inner cell mass of blastocyst-stage embryos and single blastomeres of 4-cell stage embryos. Mateizel I et al. Methods in molecular biology (Clifton,N.J.) 2012 JAN

Abstract

More than 600 human embryonic stem cell (hESC) lines have been reported today at the human European Embryonic Stem Cell Registry ( http://www.hescreg.eu/ ). Despite these high numbers,there are currently no general protocols for derivation,culture,and characterization of hESC. Moreover,data on the culture of the embryo used for the derivation (medium,day of ICM isolation) are usually not available but can have an impact on the derivation rate. We present here the protocols for derivation,culture and characterization as we applied them for the 22 hESC lines (named VUB-hESC) in our laboratory.
Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro Xia G et al. Journal of Molecular Neuroscience 2013 OCT

Abstract

Spinocerebellar ataxia type 2 (SCA2) is caused by triple nucleotidebackslashnrepeat (CAG) expansion in the coding region of the ATAXN2 gene onbackslashnchromosome 12,which produces an elongated,toxic polyglutamine tract,backslashnleading to Purkinje cell loss. There is currently no effective therapy.backslashnOne of the main obstacles that hampers therapeutic development is lackbackslashnof an ideal disease model. In this study,we have generated andbackslashncharacterized SCA2-induced pluripotent stem (iPS) cell lines as an inbackslashnvitro cell model. Dermal fibroblasts (FBs) were harvested from primarybackslashncultures of skin explants obtained from a SCA2 subject and a healthybackslashnsubject. For reprogramming,hOct4,hSox2,hKlf4,and hc-Myc werebackslashntransduced to passage-3 FBs by retroviral infection. Both SCA2 iPS andbackslashncontrol iPS cells were successfully generated and showed typical stembackslashncell growth patterns with normal karyotype. All iPS cell lines expressedbackslashnstem cell markers and differentiated in vitro into cells from threebackslashnembryonic germ layers. Upon in vitro neural differentiation,SCA2 iPSbackslashncells showed abnormality in neural rosette formation but successfullybackslashndifferentiated into neural stem cells (NSCs) and subsequent neuralbackslashncells. SCA2 and normal FBs showed a comparable level of ataxin-2backslashnexpression; whereas SCA2 NSCs showed less ataxin-2 expression thanbackslashnnormal NSCs and SCA2 FBs. Within the neural lineage,neurons had thebackslashnmost abundant expression of ataxin-2. Time-lapsed neural growth assaybackslashnindicated terminally differentiated SCA2 neural cells were short-livedbackslashncompared with control neural cells. The expanded CAG repeats of SCA2backslashnwere stable throughout reprogramming and neural differentiation. Inbackslashnconclusion,we have established the first disease-specific human SCA2backslashniPS cell line. These mutant iPS cells have the potential for neuralbackslashndifferentiation. These differentiated neural cells harboring mutationsbackslashnare invaluable for the study of SCA2 pathogenesis and therapeutic drugbackslashndevelopment.

更多信息

更多信息
物种
配方 无血清
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系